Pre-exposure prophylaxis with tixagevimab-cilgavimab protects blood cancer patients against COVID
MUSC Hollings Cancer Center oncologists found that using a combination monoclonal antibody (tixagevimab-cilgavimab) against the SARS-CoV-2 spike protein in patients with blood cancers prevented moderate and severe COVID cases. ...
Dec 16, 2022
0
18